ALEC
Alector, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.95
+5.98%Oct 16, 2026, 11:30 UTC
Alector announced pricing an underwritten offering of 36.6 million common shares at $2.05 per share, expected to generate $75.03 million in gross proceeds before expenses.
Source:Oct 5, 2026, 11:01 UTC
Alector, Inc. signed an option and license agreement with Spur Therapeutics Limited for a worldwide, royalty-bearing, non-exclusive license to engineered GCase patents, paying $15 million upon exercise plus sublicense income and royalties.
Oct 5, 2026, 11:01 UTC
Alector, Inc. signed a license agreement granting Genentech, Inc. exclusive worldwide rights to develop and commercialize its AL050 program, receiving a $100 million upfront payment and up to $1.17 billion in milestones plus tiered royalties.
Source:Sep 17, 2026, 13:30 UTC
Novartis halted development of its investigational ALS therapy VHB937 after the ASTRALS Phase 2 trial failed to meet its primary or secondary endpoints.
Source:Aug 7, 2026, 00:12 UTC
Alector reported a second-quarter loss of $0.21 per share, beating the Zacks Consensus Estimate of a loss of $0.24 and improving from a loss of $0.30 per share a year earlier.
Source:Jul 8, 2026, 21:20 UTC
GSK terminated its neuroscience collaboration agreement with Alector covering two experimental antibody drugs after both drug candidates suffered clinical setbacks.
Source: